These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 22460117)

  • 21. Accelerating access to treatments for rare diseases.
    Dunoyer M
    Nat Rev Drug Discov; 2011 Jun; 10(7):475-6. PubMed ID: 21701499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
    Oo C; Rusch LM
    J Clin Pharmacol; 2016 Mar; 56(3):257-9. PubMed ID: 26211513
    [No Abstract]   [Full Text] [Related]  

  • 23. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-authorisation assessment of orphan drugs.
    Hollak CEM; Biegstraaten M; Levi M; Hagendijk R
    Lancet; 2015 Nov; 386(10007):1940-1941. PubMed ID: 26841744
    [No Abstract]   [Full Text] [Related]  

  • 25. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

  • 26. The routes to orphan drug designation--our recent experience at the FDA.
    Lev D; Thorat C; Phillips I; Thomas M; Imoisili MA
    Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120
    [No Abstract]   [Full Text] [Related]  

  • 27. Protein replacement therapies for rare diseases: a breeze for regulatory approval?
    Gorzelany JA; de Souza MP
    Sci Transl Med; 2013 Mar; 5(178):178fs10. PubMed ID: 23536010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adopting orphan drugs--two dozen years of treating rare diseases.
    Haffner ME
    N Engl J Med; 2006 Feb; 354(5):445-7. PubMed ID: 16452556
    [No Abstract]   [Full Text] [Related]  

  • 29. Outrageous prices of orphan drugs: a call for collaboration.
    Luzzatto L; Hyry HI; Schieppati A; Costa E; Simoens S; Schaefer F; Roos JCP; Merlini G; Kääriäinen H; Garattini S; Hollak CE; Remuzzi G;
    Lancet; 2018 Sep; 392(10149):791-794. PubMed ID: 30037734
    [No Abstract]   [Full Text] [Related]  

  • 30. The Orphan Drug Act Revisited.
    Thomas S; Caplan A
    JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155
    [No Abstract]   [Full Text] [Related]  

  • 31. Predictors of orphan drug approval in the European Union.
    Heemstra HE; de Vrueh RL; van Weely S; Büller HA; Leufkens HG
    Eur J Clin Pharmacol; 2008 May; 64(5):545-52. PubMed ID: 18210097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical trials of orphan medicines.
    Buckley BM
    Lancet; 2008 Jun; 371(9629):2051-5. PubMed ID: 18555919
    [No Abstract]   [Full Text] [Related]  

  • 33. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drugs and orphan diseases.
    Blin O; Micallef J
    Therapie; 2020 Apr; 75(2):131-132. PubMed ID: 32247679
    [No Abstract]   [Full Text] [Related]  

  • 35. 10th European Conference on Rare Diseases & Orphan Products (ECRD 2020).
    Orphanet J Rare Dis; 2020 Nov; 15(Suppl 1):310. PubMed ID: 33168048
    [No Abstract]   [Full Text] [Related]  

  • 36. Promoting the development of drugs against rare diseases: what more should be done?
    Westermark K; Llinares J
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):541-3. PubMed ID: 23186396
    [No Abstract]   [Full Text] [Related]  

  • 37. [The legal regulation of life cycle of orphan pharmaceuticals].
    Gildeyeva GN; Kartavtsova TV
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M; Kubácková K; Palágyi M; Smíd M
    Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pediatric Orphan Drug Indications: 2010-2018.
    Kimmel L; Conti RM; Volerman A; Chua KP
    Pediatrics; 2020 Apr; 145(4):. PubMed ID: 32127360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Orphan Drugs and Their Impact on Pharmaceutical Development.
    Attwood MM; Rask-Andersen M; Schiöth HB
    Trends Pharmacol Sci; 2018 Jun; 39(6):525-535. PubMed ID: 29779531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.